Actavis plc is acquiring four currently marketed products from Akorn Inc. and Hi-Tech Pharmacal Co.


Actavis, Akorn, Hi-Tech Pharmacal, ciprofloxacin hydrochloride ophthalmic solution, levofloxacin ophthalmic solution, lidocaine hydrochloride jelly, lidocaine/prilocaine topical cream, Siggi Olafsson, Actavis Pharma.














































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Actavis buys ophthalmic, topical products from Akorn

April 18th, 2014

DUBLIN, Ireland – Actavis plc is acquiring four currently marketed products from Akorn Inc. and Hi-Tech Pharmacal Co.

The agreements include three products marketed under Abbreviated New Drug Applications (ANDAs) — ciprofloxacin hydrochloride ophthalmic solution, levofloxacin ophthalmic solution and lidocaine hydrochloride jelly — and lidocaine/prilocaine topical cream, which is marketed under a New Drug Application (NDA), Actavis said Thursday.

In addition, the purchase includes one product under development. Financial terms of the agreements weren't disclosed.

"The acquisition of these products will complement our expanding portfolio of topical and ophthalmic generic products and further strengthen our position as a leader in developing and marketing the complex, high-barrier products that provide enhanced value," stated Siggi Olafsson, president of Actavis Pharma.

Actavis said the closing of the purchase agreements are contingent on the completion of Akorn's acquisition of Hi-Tech Pharmacal. Akorn announced on Thursday that it closed the Hi-Tech acquisition.

Advertisement